Exit Interviews Examining Changes to Mood and Work/Productivity Impacts Related to Vasomotor Symptoms: Perspectives of Postmenopausal Women Receiving Elinzanetant in Phase III Clinical Trials
This study provides novel insights into women's experiences of VMS-associated impacts on mood and work/productivity, highlighting the emotional and economic burdens of VMS. Data support and contextualize the treatment benefits of elinzanetant on mood and work/productivity that are meaningful to women.
Authors
- Christian Seitz (ORCID: https://orcid.org/0000-0003-2315-9148)
- Helena Bradley (ORCID: https://orcid.org/0000-0002-7077-2183)
- Claudia Haberland (ORCID: https://orcid.org/0000-0002-5533-1881)
- Sophie Whyman
- Adam Gater (ORCID: https://orcid.org/0000-0001-9582-8596)
- Asha Lehane (ORCID: https://orcid.org/0000-0003-1689-569X)
- Melissa Barclay (ORCID: https://orcid.org/0000-0003-1822-6641)
- Heidi Wikström (ORCID: https://orcid.org/0000-0001-9744-8415)
- Andrew Trigg (ORCID: https://orcid.org/0000-0002-1613-8042)
- Nils Schoof (ORCID: https://orcid.org/0000-0003-0343-2776)
Institutions
- Adelphi Group (United Kingdom) (GB)
- Bayer (Finland) (FI)
- Bayer (United Kingdom) (GB)
- Bayer (Germany) (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Patient
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1007/s40271-025-00748-4
- Citations
- 2
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Bayer